A Phase 1, Open-label, Fixed-sequence, 2-period Study In Healthy Volunteers To Investigate The Effect Of Multiple Doses Of Rifampin On Single Dose Glasdegib (Pf-04449913) Plasma Pharmacokinetics

Trial Profile

A Phase 1, Open-label, Fixed-sequence, 2-period Study In Healthy Volunteers To Investigate The Effect Of Multiple Doses Of Rifampin On Single Dose Glasdegib (Pf-04449913) Plasma Pharmacokinetics

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2016

At a glance

  • Drugs Glasdegib (Primary) ; Rifampicin
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 24 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 26 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top